Estado del programa
Activo, no reclutaFase
Fase 2Inmunoterapia previa permitida
SíEnsayo dirigido por el CRC
SíDrogas
Cetuximab Injection [Erbitux], HLX208Etiquetas
MSS/ MMRpComentarios
For BRAF mutant CRC, after failure of first line treatment. Targeted therapy.
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer (and head and neck cancer). It is mainly used in KRAS wild type metastatic CRC.
HLX208 – trial medication that is a BRAF V600E Inhibitor
| Ubicación | Situación |
|---|---|
| China | |
|
Fudan University Affiliated Oncology Hospital Shanghai |
Activo, no recluta |
Criterios de inclusión
Criterios de inclusión:
Age>=18Y
Good Organ Function
Expected survival time ≥ 3 months
Metastatic/recurrent advanced BRAF+ mCRC that have been diagnosed histologically and have failed first line treatment
ECOG score 0-1;
Criterios de exclusión
Criterios de exclusión:
arm 1 ： Previous treatment with BRAF inhibitors or MEK inhibitors
Symptomatic brain or meningeal metastases (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable).
Active clinical severe infection;
A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
